Aurora Cannabis Inc. delivered a strong Q3 2026 performance with a 7% increase in net revenue, driven primarily by robust international medical cannabis growth. The company reported positive free cash flow and improved margins while focusing on strategic market exits to enhance profitability.

• Net revenue increased by 7%, with a 12% rise in global medical cannabis sales, surpassing expectations.
• Adjusted gross margin improved to 62%, supported by a strong international performance with medical cannabis margins at 69%.
• Achieved positive adjusted EBITDA of $18.5 million and free cash flow of $15.5 million, maintaining a solid balance sheet with over $150 million in cash.
• Initiating exits from lower-margin Canadian consumer cannabis markets to concentrate resources on higher-margin global medical cannabis growth.
• Announced a new at-the-market equity program to raise up to $100 million for strategic investments including cultivation capacity enhancements.